Psilocybin: promising results in double-blind trials require confirmation by real-world evidence

European Medicines Agency (2016) Final Report on the Adaptive Pathways Pilot. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2016/08/WC500211526.pdf (accessed 21 October 2016).

Fantegrossi WE Woods JH Winger G (2004) Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol 15: 149–157.

Griffiths RR Johnson MW Carducci MA (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 30: 1181-1197.

Kalkman S van Thiel GJ Grobbee DE . (2015) Pragmatic randomized trials in drug development pose new ethical questions: A systematic review. Drug Discov Today 20: 856–862.

MacLean KA Johnson MW Griffiths RR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol 25: 1453–1461.

Passie T Seifert J Schneider U . (2002) The pharmacology of psilocybin. Addict Biol 7: 357–364.

Ross S Bossis A Guss J (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol 30: 1165-1180.

Zuidgeest MG Goetz I Grobbee DE ; WP3 of the GetReal Consortium. PRECIS-2 in perspective: What is next for pragmatic trials? J Clin Epidemiol. Epub ahead of print 6 March 2016. doi: 10.1016/j.jclinepi.2016.02.027.